Top Story Today
Teva Cracked Open a Door Big Pharma Thought Was Locked
Nearly every pharma company that sued to block Medicare's new drug price negotiation powers has lost. Then a federal appeals court in D.C. sent one piece of Teva's case back for a closer look, marking the first time any court has kept any challenge to the IRA's pricing framework alive. The surviving argument targets how CMS defines when generic competition lets a brand-name drug escape negotiations. It's narrow, but in a legal campaign with an almost perfect losing record, it gives the industry its first real precedent to build on.
Why it matters: The ruling won't topple the IRA's pricing program, but it signals that specific CMS implementation decisions (not the law itself) may be legally vulnerable. That distinction could shape how every pharma company with a drug approaching the negotiation list plans its strategy for years to come.
Read more →Clinical and Regulatory
The $2.7 Million Shot That Replaces a Lifetime of Eating Cornstarch
The FDA approved the first-ever treatment for glycogen storage disease type Ia, a rare condition where patients must eat raw cornstarch on a brutal round-the-clock schedule to avoid dangerous blood sugar crashes. Ultragenyx's Genglycos gene therapy reduced daily cornstarch intake by 41% versus placebo in a Phase 3 trial. It carries a $2.7 million price tag and an accelerated approval, meaning confirmatory studies are still required.
Read more →BioNTech Unveils a Two-Drug Combo Nobody Has Tried in Lung Cancer
At WCLC 2026, BioNTech presented first-ever data combining a PD-L1xVEGF bispecific antibody with an antibody-drug conjugate in advanced lung cancer. The combo earned a late-breaking oral slot, the conference equivalent of primetime TV. Full efficacy numbers are still under wraps, but BioNTech is building pumitamig into a platform drug across multiple tumor types with 15 Phase 3 programs now running company-wide.
Read more →Boehringer Hits the Brakes on an Early-Stage Pipeline Project
Boehringer Ingelheim voluntarily paused enrollment in a Phase 1 study of oral drug BI 3031185 after a safety concern. No details on severity or whether it was drug-related. For a company with roughly 80 pipeline projects, the hit is manageable; for early-stage drug development, it's a reminder that the leap from animals to humans is still the riskiest step.
Read more →Deals and Strategy
Amgen Walks Away From a $500M+ Bet on T-Cell Therapy
Three years and $30 million in, Amgen killed its TCR therapy collaboration with TScan Therapeutics, vaporizing over $500 million in potential milestones. The move reflects Amgen's pivot toward bispecific T-cell engagers over cell therapy, and highlights the broader growing pains facing TCR-T: HLA restrictions, tumor escape mechanisms, and a clinical track record that still trails CAR-T by years. TScan has $100 million in cash and about a year to prove it can stand alone.
Read more →BMS Hired a Two-Year-Old AI Startup to Design Its Next Antibody
Bristol Myers Squibb partnered with Chai Discovery, a startup valued at $1.3 billion that didn't exist in 2023, to build AI-driven antibody discovery into its R&D pipeline. Chai's models reportedly hit a near-20% success rate on designed antibodies, dwarfing traditional screening. BMS has now assembled AI partnerships covering small molecules, miniproteins, and antibodies, wiring machine learning into every corner of its discovery operation.
Read more →Market Movers
Novo's $149 Pill Could Upend the GLP-1 War
Doctors overwhelmingly prefer Lilly's Zepbound for weight loss (80% satisfaction vs. 59% for Wegovy). But Novo just priced its Wegovy pill at $149 per month, roughly half of Zepbound's self-pay cost. With many GLP-1 users quitting over affordability and Medicare's new $50/month demo program launching in July, the cheapest effective option may matter more than the clinically preferred one.
Read more →A $200 Blood Draw Could Replace a $3,000 Brain Scan for Alzheimer's
The FDA cleared C2N's PrecivityAD2 blood test for evaluating cognitive impairment in adults as young as 40, matching PET scan results 88% of the time. With two amyloid-targeting drugs now on the market and patients stuck in a diagnostic bottleneck (PET scans cost $3,000+ and aren't widely available), a simple blood draw could finally unclog the pipeline from diagnosis to treatment.
Read more →Roche Bets $750 Million That Oregon Is the Future of Drug Manufacturing
Genentech is building a $750 million fill-finish facility in Hillsboro, Oregon, doubling the campus to produce prefilled syringes and autoinjectors for its growing biologics pipeline. The project joins a massive reshoring wave: 154 facility expansions were announced across pharma in 2025 alone. Commercial operations won't start until 2031, but the investment signals Roche's confidence that injectable biologics demand isn't slowing down.
Read more →